ASH 2014: CAR-T cell therapies generate buzz
This article was originally published in Scrip
Excitement around chimeric antigen receptor (CAR) T cell therapies has been building during the past year, because of the potential to essentially cure significant numbers of patients with hard to treat cancers, and the buzz came to a fever pitch during the American Society of Hematology (ASH) annual meeting in San Francisco from 6 to 9 December.
You may also be interested in...
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.